Lead Plaintiff Deadline: October 18, 2021
See If You Qualify For Monetary Reward
Please Upload related files below
Fill in below.
Looking for more?
(1) Annovis’s ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
In order to be included in the lawsuit, you must have incurred a loss on shares of Annovis Bio purchased or acquired during the class period listed above.
If you suffered a loss in Annovis Bio during the relevant time frame, you have until October 18, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.